Waldenström macroglobulinemia

Evolution of Tumor Subclones and T-Cell Dynamics Underlie Variable Ibrutinib Responses in Waldenström Macroglobulinemia

Single-cell profiling of WM during ibrutinib therapy revealed three tumor evolution patterns, a predictive WIP score, and T-cell dysfunction linked to resistance and disease progression.

Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis